{"id":759095,"date":"2025-05-14T16:19:48","date_gmt":"2025-05-14T14:19:48","guid":{"rendered":"https:\/\/intervacc.se\/?p=759095"},"modified":"2025-05-21T16:33:30","modified_gmt":"2025-05-21T14:33:30","slug":"report-from-annual-general-meeting-in-intervacc-5","status":"publish","type":"post","link":"https:\/\/intervacc.se\/en\/report-from-annual-general-meeting-in-intervacc-5\/","title":{"rendered":"Report from Annual General Meeting in Intervacc"},"content":{"rendered":"
\n

Intervacc AB (publ) has held its Annual General Meeting (\u201dAGM\u201d) on Wednesday 14 May 2025, at which the following resolutions were made.<\/p>\n<\/div>\n\n\n\n\n\n\n

Adoption of the income statement and balance sheet<\/h2>\n\n\n\n

The AGM adopted the Board of Directors\u2019 submitted income statement and balance sheet for the parent company and the group for the financial year 2024.<\/p>\n\n\n\n

Appropriation of the company\u2019s profit or loss<\/h2>\n\n\n\n

The AGM resolved, in accordance with the Board of Directors\u2019 proposal, that no dividend shall be paid for the financial year 2024, and that the result shall be balanced in a new account.<\/p>\n\n\n\n

Discharge from liability towards the members of the Board of Directors and the CEOs<\/h2>\n\n\n\n

The AGM resolved to discharge each of the members of the Board of Directors and the CEOs who have been active during the financial year 2024, from liability for the financial year 2024.<\/p>\n\n\n\n

Board of Directors and auditor<\/h2>\n\n\n\n

The AGM resolved, in accordance with the Nomination Committee\u2019s proposal, that the Board of Director shall consist of seven Board members without any deputies.<\/p>\n\n\n\n

The AGM resolved, in accordance with the Nomination Committee\u2019s proposal, to re-elect H\u00e5kan Bj\u00f6rklund, Lisen Bratt Fredricson, Lennart Johansson, Camilla Ramfelt McCarthy, Mathias Uhlen, and Emil Billb\u00e4ck, and to elect Bj\u00f6rn Odlander as Board members for the period up to and including the next AGM. H\u00e5kan Bj\u00f6rklund was re-elected as the Board of Directors\u2019 chairperson for the period up to and including the next AGM.<\/p>\n\n\n\n

The AGM resolved, in accordance with the Nomination Committee\u2019s proposal, that the fees to the Board of Directors shall be paid with SEK 280,000 to the Board of Directors\u2019 chairperson and SEK 130,000 to each of the other Board members.<\/p>\n\n\n\n

The AGM resolved, in accordance with the Nomination Committee\u2019s proposal, to re-elect the registered public accounting firm \u00d6hrlings PricewaterhouseCoopers AB as the company\u2019s auditor for the period up to and including the next AGM, which intends to appoint the authorised public accountant Niclas Bergenmo as auditor in charge.
The AGM resolved that fees to the auditor shall be paid according to the current account.
\u2003<\/p>\n\n\n\n

Authorisation regarding issues<\/h2>\n\n\n\n

The AGM resolved, in accordance with the Board of Directors\u2019 proposal, to authorise the Board of Directors, within the limits of the Articles of Association, with or without deviation from the shareholders\u2019 preferential rights, on one or more occasions, until the next AGM, to resolve to increase the company\u2019s share capital through issues of new shares, warrants and\/or convertibles in the company. The total number of shares covered by such new issues may correspond to a total of no more than ten (10) percent of the shares in the company at the time of the AGM 2025.<\/p>\n\n\n\n

For more information please contact:<\/strong>
Jonas Sohlman, CEO
Phone: +46 (0)8 120 10 600
E-mail: jonas.sohlman@intervacc.se<\/p>\n\n\n\n

The information was submitted for publication, through the agency of the contact person set out above on May 14, 2025, 16.15 CET.<\/em><\/p>\n\n\n\n

About Intervacc<\/strong>
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company\u2019s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company\u00b4s research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.<\/p>\n\n\n\n

Contact information for Certified Adviser<\/strong>
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 \u2013 684 211 10<\/p>\n","protected":false},"excerpt":{"rendered":"

Intervacc AB (publ) has held its Annual General Meeting (\u201dAGM\u201d) on Wednesday 14 May 2025, at which the following resolutions […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[27],"tags":[],"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/759095"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=759095"}],"version-history":[{"count":8,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/759095\/revisions"}],"predecessor-version":[{"id":761131,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/759095\/revisions\/761131"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=759095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/categories?post=759095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/tags?post=759095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}